Abstract 2123P
Background
Immuno-nutritional scores like neutrophil-lymphocyte ratio (NLR), prognostic nutritional index (PNI), modified Glasgow prognostic score (mGPS) and controlling nutritional status (CONUT) have been developed to reflect the chronic inflammatory state and malnutrition induced by cancer, and to predict clinical outcomes. This study aims to investigate the prognostic value of these scores in hospitalized patients with lung cancer as we know that unscheduled admission in patients with cancer may imply organ fragility.
Methods
In this retrospective study, we examined patients with lung cancer and unscheduled hospitalizations that took place between June 2021 and May 2022 within the Medical Oncology Service of La Paz University Hospital in Madrid, Spain.
The optimal cutoff for continuous variables was evaluated with Youden index. Survival since admission was estimated with the Kaplan-Meier method. Univariate and multivariate analyses were performed by Cox regression model to determine independent prognostic factors. Areas under the curve (AUCs) or ROCs were calculated to evaluate the discriminatory ability.
Results
We admitted 158 patients with a median age of 68 years, majority of male (66.5%) and stage IV predominance (84.8%). The median follow-up was 14.9 months. The median overall survival since admission was 3.3 months (95%CI: 1.86-7.74). The optimal cut-off value for NLR was calculated to be 6 (Youden index=0.2) and for PNI was 40 (Youden index=0.1). In univariate analysis, poorer survival was associated with NLR>6 (1.87 vs 7.40 months, p=0.006, HR 1.67, 95%CI 1.16-2.42) and PNI<40 (1.67 vs 4.97 months, p=0.044, HR 1.49, 95%CI 1.01-2.20) and was not associated with CONUT (p=0.70) or mGPS (p=0.067). In the multivariate analysis only NLR>6 was an independent prognostic factor (p=0.042, HR 1.61, 95%CI 1.02-2.57). The ROC curve to evaluate the discriminatory ability of 30-day mortality was only significant in the case of NLR>6 (p=0.035, AUC 0.599, 95%CI 0.51-0.69).
Conclusions
In our setting, NLR was the most robust score for estimating prognosis in hospitalized patients with lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06
2046P - The importance of communicating bad news in medical education
Presenter: Georgios Goumas
Session: Poster session 06
2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice
Presenter: Florian Scotté
Session: Poster session 06
2048P - Frequency and clinical relevance of drug-drug interactions with oxycodone among patients with cancer
Presenter: Lotte Hulskotte
Session: Poster session 06
2049P - Osimertinib-related muscle cramps as a common adverse event: A real-world data analysis in the post-approval setting
Presenter: Gisele Moreira
Session: Poster session 06
2050P - Integrating ayurveda herbs with standard of care for management of cancer or cancer treatment related anorexia
Presenter: Yogesh Bendale
Session: Poster session 06
2051P - E-PRO within comprehensive companion program for patients undergoing systemic cancer treatment to reduce emergency visits and inpatient admission in a Peruvian institution
Presenter: Patricia Rioja Viera
Session: Poster session 06
2052P - Adverse events in FLOT chemotherapy for locally advanced gastric cancer: An observational study of pre- and post-operative toxicity profiles
Presenter: Camila Oliveira
Session: Poster session 06
2053P - Dehospitalization through outpatient drug release in clinical pharmacy as a strategic cost-minimization action in a public oncology hospital in the Eastern Amazon: A quantitative analysis
Presenter: Kalysta Borges
Session: Poster session 06
2054P - Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
Presenter: Colin Vercueil
Session: Poster session 06